Market: NASD |
Currency: USD
Address: 142 Sansome Street
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
📈 89bio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$30.00
-
Upside/Downside from Analyst Target:
218.47%
-
Broker Call:
16
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-07
-
EPS Estimate:
-0.48
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for 89bio, Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-07 | -0.71 |
| 2025-05-01 | -0.49 |
| 2025-02-27 | -1.02 |
| 2024-11-07 | -1.39 |
| 2024-08-05 | -0.48 |
| 2024-05-09 | -0.54 |
| 2024-02-29 | -0.5 |
| 2023-11-09 | -0.45 |
| 2023-08-09 | -0.52 |
| 2023-05-08 | -0.54 |
| 2023-03-10 | -0.48 |
| 2022-11-10 | -0.57 |
| 2022-08-11 | -1.23 |
| 2022-05-11 | -1.26 |
| 2022-03-24 | -1.3 |
| 2021-11-11 | -1.41 |
| 2021-08-13 | -1.03 |
| 2021-05-12 | -0.74 |
| 2021-03-24 | -0.63 |
| 2020-11-10 | -0.86 |
| 2020-08-13 | -0.85 |
| 2020-05-13 | -0.76 |
| 2020-03-18 | -2.58 |
| 2019-12-18 | -1.36 |
📰 Related News & Research
No related articles found for "89bio inc".
